Screener
Merck & Co. MRK Q3 2026 earnings
Reported October 29, 2026 · Before market open
Revenue$18.1BBeat by $754.2M
Adjusted EPS$2.49Beat by $0.40
Revenue estimate$17.3B
EPS estimate$2.09
“Our science-led strategy is transforming our business. The potentially practice-changing advances in oncology presented at last weekend's ESMO meeting, including new data for our antibody-drug conjugate sac-TMT and the first Phase 3 validation of a therapeutic cancer vaccine, further clinically de-risk the substantial long-term opportunity of our late-phase pipeline. With positive momentum across multiple therapeutic areas, I'm increasingly confident in our ability to deliver long-term value for patients and shareholders.”
Earnings data and commentary were extracted with AI from company filings and may contain errors. Verify important details in the filing.
Next report
Date not yet announcedFinancials
Q3 2026Income statement
Valuation & ratios
Valuation
as of 11/02/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Merck & Co. report Q3 2026 earnings?
- Merck & Co. (MRK) reported Q3 2026 earnings on October 29, 2026 before market open.
- What were Merck & Co.'s Q3 2026 revenue and EPS?
- Merck & Co. reported revenue of $18.1B and adjusted eps of $2.49 for Q3 2026.
- Did Merck & Co. beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $17.3B by $754.2M. EPS beat the consensus estimate of $2.09 by $0.40.
- How did Merck & Co.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 4.7% from $17.3B a year earlier.
- Where can I find Merck & Co.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001104659-26-119825) directly on SEC EDGAR. The filing index links above go to sec.gov.
